Testagen: what the research shows

  • By Reed Calder
  • Last reviewed Nov 12, 2026
  • 17 studies and official documents checked

In short

Testagen is a lab-made peptide of four amino acids (Lys-Glu-Asp-Gly, or KEDG) from the St. Petersburg group of Vladimir Khavinson. It is sold online as a testosterone “bioregulator.” We found one study in people: a 2011 report in 36 men with chronic prostatitis and low testosterone. Twenty took a Testagen dietary-supplement capsule alongside standard treatment and 16 had standard treatment alone. Testosterone rose from 7.1 to 9.8 nmol/L with Testagen and to 7.5 without, and the Testagen group still sat under the authors’ own 11 nmol/L cutoff. The paper isn’t in PubMed, describes no placebo or blinding, and reports no side effects. The animal work is five studies from one group in chickens whose pituitary glands had been removed; none measured testosterone. It isn’t FDA-approved.

EvidenceCellAnimalHumanone 30-day study in 36 men, using a capsule; no injected form tested

You’ll often read that Testagen raises testosterone without shutting down your own production, is backed by clinical trials, cuts cell aging “3.23-fold” and comes with injection protocols. This page covers what it is, what the one human study and the animal studies tested, what the seller numbers come from, and where it stands legally.

Names and forms you’ll see

The names on Testagen products
Name What it is Studied in people?
Testagen, KEDG, Lys-Glu-Asp-Gly The trade name, the letter code and the amino-acid names for the same four amino acids: lysine, glutamic acid, aspartic acid and glycine (Khavinson et al., 2021) One 2011 study, of a capsule
Anterior pituitary peptide A name sellers use. It was designed from the amino-acid make-up of peptides extracted from the front lobe of the pituitary gland (Kuznik et al., 2011) The same study
Testagen capsules or tablets The Russian dietary supplement used in the 2011 study, with 0.100 mg of active substance in each (Rossikhin et al., 2011) Yes, once
Vials and powders Forms sold online under the Testagen name No study of these found
Testagen TDS-Testosterone A testosterone spray with the same brand name; a different product (NCT02733133) Not the peptide
KED, AEDG, AED Other Khavinson peptides with similar letters; see the comparison below Different studies

We found no entry for Testagen or KEDG in the FDA’s substance registry or in PubChem. A CAS number appears on seller catalogs only, so we don’t list one.

What Testagen is

Testagen is four amino acids: lysine, glutamic acid, aspartic acid and glycine. By our arithmetic from those four it is C17H29N5O9 and weighs about 447 daltons. Khavinson’s group designed it from the amino acids found in extracts of the front lobe of the pituitary gland and lists it for “regulation of male reproductive system function” (Kuznik et al., 2011; Khavinson et al., 2021).

The idea behind it is that very short peptides enter a cell’s nucleus and change which genes are switched on. For KEDG, what supports that is lab work: a labeled copy entered the nucleus of cultured cells, and it bound plant histones in a tube (Fedoreyeva et al., 2011; Fedoreyeva et al., 2013). None of that work measured testosterone.

What has been studied

In people: one study, 2011

  • Who and what. 36 men aged 38 to 49 in Kharkiv and Belgorod with chronic non-bacterial prostatitis, urinary symptoms and total testosterone under 11 nmol/L. 20 got standard treatment (a prostate-relaxing drug and an anti-inflammatory suppository) plus Testagen capsules; 16 got standard treatment alone. The Testagen was an oral dietary supplement taken for 30 days (Rossikhin et al., 2011).
  • Results. After 30 days, total testosterone was 9.8 nmol/L with Testagen, up from 7.1, against 7.5 with standard treatment alone. A prostatitis symptom score fell from 16.1 to 9.8 with Testagen and to 11.5 without. White cells in prostate fluid fell to 15.4 per field against 25.6, and urine flow rose to 17.4 mL/s against 15.1. LH and FSH, the pituitary signals that drive the testes, fell slightly in both groups.
  • What the paper doesn’t say. It doesn’t say how men were assigned to the groups, and describes no placebo or blinding. It reports no side effects, dropouts or follow-up beyond 30 days, and no funding or conflict statement, though it names the supplement’s maker. Its tables mark significance against each group’s own starting value only. The text and a table give different starting white-cell counts (20.8 and 28.2 per field).
  • Still low. The Testagen group’s average of 9.8 nmol/L stayed below the 11 nmol/L cutoff the authors used to define deficiency.
  • Hard to find. The paper is in a Ukrainian journal and isn’t indexed in PubMed, so a PubMed search finds no study in people.

EvidenceCellAnimalHumanone study, 36 men, a capsule for 30 days

In animals: chickens without a pituitary

  • Thyroid, 2008 to 2011. In chicks and hens whose pituitary gland had been removed, 40 days of KEDG raised thyroid-stimulating hormone and thyroid hormones and restored thyroid structure. The effect was smaller in old hens (Kuznik et al., 2008; Kuznik et al., 2011; Kuznik et al., 2011).
  • Immunity, clotting and thymus, 2010 and 2013. In the same kind of bird, injected KEDG and AEDG prevented thyroid atrophy and normalized immune and clotting measures, and the thymus recovered (Kuznik et al., 2010; Pateyk et al., 2013).
  • One group, one model. All five papers come from the same Chita team and the same pituitary-removed bird. We found no animal study of testosterone, testes, prostate or sperm after KEDG.

EvidenceCellAnimalHuman

In dishes and tubes

  • 2011 and 2013. A fluorescent copy of Testagen entered the nucleus of cultured cells and changed the glow of DNA pieces. KEDG and five other peptides bound labeled plant histones in a tube (Fedoreyeva et al., 2011; Fedoreyeva et al., 2013).
  • 2023, on a computer. A docking model suggests KEDG fits three amino-acid transporter sites. That is a calculation, not an experiment (Khavinson et al., 2023).
  • 2020 review. The developers’ review lists KEDG among peptides that activate immune-cell differentiation (Khavinson et al., 2020).

EvidenceCellAnimalHuman

The “3.23-fold” fall in cell-aging markers that seller pages credit to Testagen comes from a 2020 study of two other peptides, AEDG and KED, in human stem cells. KED lowered the markers 1.82 to 3.23 times; KEDG wasn’t tested (Sinjari et al., 2020).

The usual claims, checked

Common Testagen claims vs the studies
Claim Verdict What the studies found
It raises testosterone Mixed In one 36-man study of a supplement taken with prostatitis treatment, testosterone rose from 7.1 to 9.8 nmol/L, against 7.5 with treatment alone (Rossikhin et al., 2011). No placebo or blinding is described, nobody has repeated it, and no animal study measured testosterone
It reduces prostate inflammation Mixed In the same study, white cells in prostate fluid and a symptom score fell more with Testagen. The text and a table disagree on the starting count (Rossikhin et al., 2011). One study, in men with prostatitis
It raises testosterone without switching off your own production, unlike TRT Untested The one study measured LH and FSH, and both fell slightly in both groups. It didn’t compare Testagen with testosterone therapy and didn’t test for suppression (Rossikhin et al., 2011)
It helps fertility, testes or sperm Untested We found no study of KEDG that measured sperm, testis structure or fertility in a person or an animal
It restores thyroid function Untested It raised thyroid hormones in chickens and hens whose pituitary gland had been removed (Kuznik et al., 2011). We found no study in an animal with an intact pituitary or in a person
It slows cell aging by up to 3.23-fold Contradicted That number is for KED, a three-amino-acid peptide, in human stem cells (Sinjari et al., 2020). We found no senescence study of KEDG
It enters the nucleus and binds DNA and histones Mixed A labeled copy entered cultured cells’ nuclei and bound plant histones in a tube (Fedoreyeva et al., 2011; Fedoreyeva et al., 2013). We found no test in a living body, and none that links it to testosterone
It acts on Leydig cells and steroid-making genes Untested We found no study that measured Leydig cells, StAR, CYP11A1 or any testis gene after KEDG
It is safe, with minimal side effects Untested The only human paper reports no side effects and says nothing about checking for them (Rossikhin et al., 2011). We found no safety study
It works for women Untested We found no study of KEDG in women
It is a substitute for testosterone therapy or hCG Untested No study compared it with either. The one human study added it to prostatitis treatment (Rossikhin et al., 2011)
Injection protocols online come from the research Contradicted The one human study used oral capsules for 30 days (Rossikhin et al., 2011). The chicken studies injected it. We found no study of an injected form in a person
It is FDA-approved Contradicted No. The FDA’s approved-drug data return no product under its names (openFDA Drugs@FDA), and its safety-risk page doesn’t name it (FDA, 2026)

Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.

Testagen and its look-alikes

Testagen compared with the peptides it is mixed up with
Testagen (KEDG) KED (Vesugen) AEDG (Epitalon) AED (Cartalax)
Amino acids Four Three Four Three
Listed by its developers for Male reproductive system Blood vessels Pineal gland and aging Cartilage and skin cells
Where it was studied Chickens without a pituitary; one 2011 study in 36 men Human stem cells in a dish (Sinjari et al., 2020) Cells, animals and small human studies; see the Epitalon page Cells and rats, none in people; see the Cartalax page

Seller pages and some AI summaries swap these letters. A result for KED or AEDG isn’t a result for Testagen. For the rest of the family, see the peptide bioregulators page.

What the studies used

Amounts used in the Testagen studies
Study What was tested Amount reported
Rossikhin et al., 2011 36 men with prostatitis; oral supplement Two capsules with food, twice a day, for 30 days; each held 0.100 mg of active substance (0.4 mg a day by our arithmetic)
Kuznik et al., 2008; Kuznik et al., 2011 Chickens and hens without a pituitary For 40 days; the abstracts give no amount
Fedoreyeva et al., 2011; Fedoreyeva et al., 2013 Cells and tubes Not stated in the abstracts

A capsule in a 30-day study isn’t a plan for anyone else, and no study compares it with an injection. We found no dose-finding, blood-level or injected-form study in people. The vial sizes sold online don’t come from any study. These are amounts from studies, not advice for anyone to use.

Side effects and safety

  • In people. The only study reports no side effects and doesn’t say whether anyone looked for them (Rossikhin et al., 2011).
  • Hormones. LH and FSH fell slightly and testosterone rose in the Testagen group. Nobody checked sperm, estradiol or thyroid hormones in people.
  • In animals. The chicken abstracts report restored thyroid and thymus structure and no harm, but none was a safety study (Kuznik et al., 2011; Pateyk et al., 2013).
  • What is in the bottle. We found no independent analysis of Testagen vials, powders or capsules sold online.
  • Not studied. Injection in people, men without prostatitis, women, use beyond 30 days, fertility, and any mix with testosterone or other peptides.

Side effects people report from online products aren’t covered here; they come from users, not studies.

Legal and approval status

  • Not an approved drug. The FDA’s approved-drug data return no product under Testagen or KEDG (openFDA Drugs@FDA), and its page of bulk substances that may present significant safety risks doesn’t name it (FDA, 2026).
  • A Russian supplement. In the 2011 study it was a dietary supplement, which isn’t a drug approval (Rossikhin et al., 2011).
  • No registered trial of the peptide. ClinicalTrials.gov’s only “Testagen” record is a testosterone spray with the same brand name, not the peptide (NCT02733133).
  • Not in the October 2026 HHS policy. That temporary policy covers six other peptides (Reuters, 2026).
  • Sport. The World Anti-Doping Agency’s 2026 list doesn’t name it, but its S0 class prohibits any substance with no government approval for human therapeutic use (WADA, 2026).
  • “Research use only” vials and any use in people aren’t approved.

What to look for if you research it

We don’t name or link sellers. These checks come from the studies and registries:

  • The letters. Testagen is KEDG, four amino acids. A result for KED (Vesugen) or AEDG (Epitalon) isn’t a result for it.
  • Which form. The one human study used an oral capsule. A page selling injection vials has no study of that form behind it.
  • Who the men were. They had prostatitis and low testosterone; a result there says nothing about healthy men or women.
  • The comparison. The control group had standard treatment, not a placebo, and nobody was blinded as far as the paper says.
  • The animals. Chickens without a pituitary gland are a thyroid model, not a testosterone one.
  • The name. A testosterone spray in a registered trial carries the Testagen brand; it isn’t the peptide.

Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.

What’s still unknown

  • Whether the testosterone rise holds up in a placebo-controlled, blinded trial.
  • Whether it does anything in men without prostatitis, or in women.
  • Whether an injected form does anything, or is even absorbed.
  • Whether it changes sperm count, fertility or the testes, which no study measured.
  • Whether it is safe beyond 30 days or alongside testosterone.
  • Whether anyone outside the developers’ circle gets the same results.

Retracted and flagged studies

A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.

We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention Testagen. We recheck every month. Last checked Nov 12, 2026.

We found no retracted, withdrawn or flagged studies that mention Testagen.

Studies this page relies on

Status of every study cited on this page
Study Published in Status
Kuznik et al., 2008 Bull Exp Biol Med No retraction or concern
Kuznik et al., 2010 Patol Fiziol Eksp Ter No retraction or concern
Kuznik et al., 2011 Adv Gerontol No retraction or concern
Fedoreyeva et al., 2011 Biochemistry (Mosc) No retraction or concern
Kuznik et al., 2011 Bull Exp Biol Med No retraction or concern
Fedoreyeva et al., 2013 Biochemistry (Mosc) No retraction or concern
Pateyk et al., 2013 Bull Exp Biol Med No retraction or concern
Sinjari et al., 2020 Stem Cell Rev Rep No retraction or concern
Khavinson et al., 2020 Stem Cell Rev Rep No retraction or concern
Khavinson et al., 2021 Molecules No retraction or concern
Khavinson et al., 2023 Biomolecules No retraction or concern

Bring your questions to other researchers

Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.

Questions

What is Testagen?

A lab-made peptide of four amino acids, lysine, glutamic acid, aspartic acid and glycine (KEDG), from Vladimir Khavinson’s group. It was designed from amino acids in pituitary extracts (Khavinson et al., 2021; Kuznik et al., 2011).

What does Testagen peptide do?

It is sold for testosterone and the prostate. We found one 36-man study of a capsule, where testosterone rose, and chicken studies of thyroid and thymus (Rossikhin et al., 2011; Kuznik et al., 2011).

Can Testagen raise testosterone?

In one 2011 study of 36 men with prostatitis, testosterone rose from 7.1 to 9.8 nmol/L with Testagen and to 7.5 without. It describes no placebo or blinding and hasn’t been repeated (Rossikhin et al., 2011).

Is Testagen the same as testosterone?

No. It is a four-amino-acid peptide, not a hormone, and the one study measured testosterone as an outcome (Rossikhin et al., 2011).

Does Testagen work?

It is unproven. There is one small study in people, and the animal studies are chickens without a pituitary, none measuring testosterone (Rossikhin et al., 2011; Kuznik et al., 2011).

Is Testagen safe?

Not shown. The one human paper reports no side effects and says nothing about checking for them, and we found no safety study (Rossikhin et al., 2011).

What are the side effects of Testagen?

Unknown. The only human study reports none, which isn’t the same as testing for them. Side effects people report from online products come from users, not studies.

What is the Testagen dosage?

We don’t give dosing advice. The one human study used two capsules with food, twice a day, for 30 days, each holding 0.100 mg of active substance (Rossikhin et al., 2011). We found no study of an injected form.

Can you inject Testagen?

The chicken studies injected it, but we found no study of an injected form in a person. The one human study used oral capsules (Kuznik et al., 2010; Rossikhin et al., 2011).

What is the best peptide to increase testosterone?

We don’t rank peptides for it. Testagen has one small human study and no placebo-controlled trial; see the sexual health page for the compounds with human records.

Is Testagen an alternative to TRT or hCG?

Not shown. No study compared it with either, and the one human study added it to prostatitis treatment (Rossikhin et al., 2011).

Is Testagen for women?

We found no study of it in women.

Does Testagen affect the thyroid?

In chickens and hens whose pituitary gland had been removed it raised thyroid hormones and restored thyroid structure (Kuznik et al., 2011). We found no thyroid study in people.

Is Testagen the same as Epitalon or Vesugen?

No. Testagen is KEDG, Epitalon is AEDG and Vesugen is KED. The “3.23-fold” senescence figure on seller pages is for KED (Sinjari et al., 2020). See the Epitalon page.

Is Testagen FDA approved or legal?

It isn’t an approved drug, and the FDA’s approved-drug data return no product under its names (openFDA Drugs@FDA). Our guide to what to look for covers the routes people use.

Sources

  1. Rossikhin VV, et al. Efficacy of testosterone synthesis inductor application “Testagen” in androgenic deficiency in patients with chronic abacterial prostatitis. Probl Endocr Pathol. 2011;36(2):17-22. In Russian; not indexed in PubMed. DOI
  2. Kuznik BI, et al. Effect of tetrapeptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the structure and function of the thyroid gland in neonatally hypophysectomized chickens. Bull Exp Biol Med. 2008;145(1):104-7. PubMed 19024016
  3. Kuznik BI, et al. [Effects of hypophyseal Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly synthetic peptides on immunity, hemostasis, morphology and functions of the thyroid gland in neonatally hypophysectomized chicken and one-year-old birds]. Patol Fiziol Eksp Ter. 2010(1):14-8. In Russian. PubMed 20731122
  4. Kuznik BI, et al. [Effects of Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly peptides on hormonal activity and thyroid morphology in hypophysectomized mature and old birds]. Adv Gerontol. 2011;24(1):93-8. In Russian. PubMed 21809626
  5. Kuznik BI, et al. Effects of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on hormonal activity and structure of the thyroid gland in hypophysectomized young chickens and old hens. Bull Exp Biol Med. 2011;150(4):495-9. PubMed 22268052
  6. Pateyk AV, et al. Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds. Bull Exp Biol Med. 2013;154(5):681-5. PubMed 23658898
  7. Fedoreyeva LI, et al. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-9. PubMed 22117547
  8. Fedoreyeva LI, et al. Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides. Biochemistry (Mosc). 2013;78(2):166-75. PubMed 23581987
  9. Khavinson VK, et al. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules. 2023;13(3):552. PubMed 36979488
  10. Khavinson V, et al. Peptide Regulation of Cell Differentiation. Stem Cell Rev Rep. 2020;16(1):118-125. PubMed 31808038
  11. Khavinson VK, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PubMed 34834147
  12. Sinjari B, et al. Short Peptides Protect Oral Stem Cells from Ageing. Stem Cell Rev Rep. 2020;16(1):159-166. PubMed 31677028
  13. ClinicalTrials.gov. NCT02733133: Testagen TDS-Testosterone transference study (Transdermal Delivery Solutions Corp), a testosterone spray; the only ClinicalTrials.gov record under the name Testagen, November 12, 2026. Record
  14. U.S. Food and Drug Administration. openFDA Drugs@FDA: searches for Testagen and KEDG, November 12, 2026: no match. openFDA
  15. U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
  16. World Anti-Doping Agency. 2026 Prohibited List, section S0. WADA document
  17. Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article

Last reviewed Nov 12, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.